Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Korell, Felix, Laier, Sascha, Sauer, Sandra, Veelken, Kaya, Hennemann, Hannah, Schubert, Maria-Luisa, Sauer, Tim, Pavel, Petra, Mueller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael, Schmitt, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290830/
https://www.ncbi.nlm.nih.gov/pubmed/32429189
http://dx.doi.org/10.3390/cells9051225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290830/
https://www.ncbi.nlm.nih.gov/pubmed/32429189
http://dx.doi.org/10.3390/cells9051225

Ejemplares similares